The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: A potential oral therapy for multiple sclerosis

Bruno Gran, N. Tabibzadeh, A. Martin, E. S. Ventura, J. H. Ware, G. X. Zhang, J. L. Parr, A. R. Kennedy, A. M. Rostami

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Available treatments for multiple sclerosis (MS) require frequent injections and have significant side effects. Proteases generated during inflammation are involved in the induction of tissue damage during inflammatory demyelination in the central nervous system (CNS). The Bowman-Birk Inhibitor (BBI), a soy-derived protease inhibitor with anti-carcinogenic and anti-inflammatory properties, has been shown to be well tolerated in clinical trials for pre-cancerous conditions, such as oral leukoplakia and the inflammatory disease, ulcerative colitis. We hypothesized that BBI may modulate experimental autoimmune encephalomyelitis (EAE), an animal model of MS. The BBI concentrate (BBIC), a soybean extract enriched in BBI, was administered to myelin basic protein (MBP)-immunized Lewis rats by gastric gavage in different treatment regimens, during the induction or the effector phase of disease. BBIC significantly delayed disease onset and suppressed disease severity, clinically and pathologically, in all treatment protocols. Both in vitro and ex vivo, BBIC inhibited MBP-specific proliferation of lymph node cells. BBIC reduced the activity of matrix metalloproteinase (MMP)-2 and -9 in spleen cell supernatants and was detected in the CNS of treated rats. BBIC suppresses EAE, it can be administered orally, and it is safe and relatively inexpensive. It may have a therapeutic role in patients with MS.

Original languageEnglish (US)
Pages (from-to)688-697
Number of pages10
JournalMultiple Sclerosis
Volume12
Issue number6
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Autoimmune Experimental Encephalomyelitis
Protease Inhibitors
Multiple Sclerosis
Myelin Basic Protein
Central Nervous System
Oral Leukoplakia
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Demyelinating Diseases
Therapeutics
Clinical Protocols
Ulcerative Colitis
Soybeans
Stomach
Peptide Hydrolases
Anti-Inflammatory Agents
Spleen
Animal Models
Lymph Nodes
Clinical Trials

Keywords

  • Experimental autoimmune encephalomyelitis
  • Immunology
  • Matrix metalloproteinase
  • Multiple sclerosis
  • Protease inhibitor
  • Therapies

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis : A potential oral therapy for multiple sclerosis. / Gran, Bruno; Tabibzadeh, N.; Martin, A.; Ventura, E. S.; Ware, J. H.; Zhang, G. X.; Parr, J. L.; Kennedy, A. R.; Rostami, A. M.

In: Multiple Sclerosis, Vol. 12, No. 6, 01.12.2006, p. 688-697.

Research output: Contribution to journalArticle

Gran, Bruno ; Tabibzadeh, N. ; Martin, A. ; Ventura, E. S. ; Ware, J. H. ; Zhang, G. X. ; Parr, J. L. ; Kennedy, A. R. ; Rostami, A. M. / The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis : A potential oral therapy for multiple sclerosis. In: Multiple Sclerosis. 2006 ; Vol. 12, No. 6. pp. 688-697.
@article{f3f7fecf5634429abe48ce37155ccc3e,
title = "The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: A potential oral therapy for multiple sclerosis",
abstract = "Available treatments for multiple sclerosis (MS) require frequent injections and have significant side effects. Proteases generated during inflammation are involved in the induction of tissue damage during inflammatory demyelination in the central nervous system (CNS). The Bowman-Birk Inhibitor (BBI), a soy-derived protease inhibitor with anti-carcinogenic and anti-inflammatory properties, has been shown to be well tolerated in clinical trials for pre-cancerous conditions, such as oral leukoplakia and the inflammatory disease, ulcerative colitis. We hypothesized that BBI may modulate experimental autoimmune encephalomyelitis (EAE), an animal model of MS. The BBI concentrate (BBIC), a soybean extract enriched in BBI, was administered to myelin basic protein (MBP)-immunized Lewis rats by gastric gavage in different treatment regimens, during the induction or the effector phase of disease. BBIC significantly delayed disease onset and suppressed disease severity, clinically and pathologically, in all treatment protocols. Both in vitro and ex vivo, BBIC inhibited MBP-specific proliferation of lymph node cells. BBIC reduced the activity of matrix metalloproteinase (MMP)-2 and -9 in spleen cell supernatants and was detected in the CNS of treated rats. BBIC suppresses EAE, it can be administered orally, and it is safe and relatively inexpensive. It may have a therapeutic role in patients with MS.",
keywords = "Experimental autoimmune encephalomyelitis, Immunology, Matrix metalloproteinase, Multiple sclerosis, Protease inhibitor, Therapies",
author = "Bruno Gran and N. Tabibzadeh and A. Martin and Ventura, {E. S.} and Ware, {J. H.} and Zhang, {G. X.} and Parr, {J. L.} and Kennedy, {A. R.} and Rostami, {A. M.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1177/1352458506070769",
language = "English (US)",
volume = "12",
pages = "688--697",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis

T2 - A potential oral therapy for multiple sclerosis

AU - Gran, Bruno

AU - Tabibzadeh, N.

AU - Martin, A.

AU - Ventura, E. S.

AU - Ware, J. H.

AU - Zhang, G. X.

AU - Parr, J. L.

AU - Kennedy, A. R.

AU - Rostami, A. M.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Available treatments for multiple sclerosis (MS) require frequent injections and have significant side effects. Proteases generated during inflammation are involved in the induction of tissue damage during inflammatory demyelination in the central nervous system (CNS). The Bowman-Birk Inhibitor (BBI), a soy-derived protease inhibitor with anti-carcinogenic and anti-inflammatory properties, has been shown to be well tolerated in clinical trials for pre-cancerous conditions, such as oral leukoplakia and the inflammatory disease, ulcerative colitis. We hypothesized that BBI may modulate experimental autoimmune encephalomyelitis (EAE), an animal model of MS. The BBI concentrate (BBIC), a soybean extract enriched in BBI, was administered to myelin basic protein (MBP)-immunized Lewis rats by gastric gavage in different treatment regimens, during the induction or the effector phase of disease. BBIC significantly delayed disease onset and suppressed disease severity, clinically and pathologically, in all treatment protocols. Both in vitro and ex vivo, BBIC inhibited MBP-specific proliferation of lymph node cells. BBIC reduced the activity of matrix metalloproteinase (MMP)-2 and -9 in spleen cell supernatants and was detected in the CNS of treated rats. BBIC suppresses EAE, it can be administered orally, and it is safe and relatively inexpensive. It may have a therapeutic role in patients with MS.

AB - Available treatments for multiple sclerosis (MS) require frequent injections and have significant side effects. Proteases generated during inflammation are involved in the induction of tissue damage during inflammatory demyelination in the central nervous system (CNS). The Bowman-Birk Inhibitor (BBI), a soy-derived protease inhibitor with anti-carcinogenic and anti-inflammatory properties, has been shown to be well tolerated in clinical trials for pre-cancerous conditions, such as oral leukoplakia and the inflammatory disease, ulcerative colitis. We hypothesized that BBI may modulate experimental autoimmune encephalomyelitis (EAE), an animal model of MS. The BBI concentrate (BBIC), a soybean extract enriched in BBI, was administered to myelin basic protein (MBP)-immunized Lewis rats by gastric gavage in different treatment regimens, during the induction or the effector phase of disease. BBIC significantly delayed disease onset and suppressed disease severity, clinically and pathologically, in all treatment protocols. Both in vitro and ex vivo, BBIC inhibited MBP-specific proliferation of lymph node cells. BBIC reduced the activity of matrix metalloproteinase (MMP)-2 and -9 in spleen cell supernatants and was detected in the CNS of treated rats. BBIC suppresses EAE, it can be administered orally, and it is safe and relatively inexpensive. It may have a therapeutic role in patients with MS.

KW - Experimental autoimmune encephalomyelitis

KW - Immunology

KW - Matrix metalloproteinase

KW - Multiple sclerosis

KW - Protease inhibitor

KW - Therapies

UR - http://www.scopus.com/inward/record.url?scp=33846321902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846321902&partnerID=8YFLogxK

U2 - 10.1177/1352458506070769

DO - 10.1177/1352458506070769

M3 - Article

C2 - 17262995

AN - SCOPUS:33846321902

VL - 12

SP - 688

EP - 697

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

IS - 6

ER -